About SynapDx
SynapDx is a company based in Southborough (United States) founded in 2010. It operates as a D2C and B2C. SynapDx has raised $32.75 million across 5 funding rounds from investors including LabCorp, Flare Capital Partners and North Bridge Venture Partners. SynapDx offers products and services including Spectros 280 IU, Genotropin 36 IU, Semaglutide 5 mg, and Zptropin 160 IU. SynapDx operates in a competitive market with competitors including Linus Biotechnology, Lineagen, MARAbio, SensOmics and Pediatric Bioscience, among others.
- Headquarter Southborough, United States
- SectorsHealthcareConsumer
- Email••••••••
- Website synapdx.com
- Social X
- Legal Name Thesah
- Total Equity Funding$32.75M (USD)
in 5 rounds
- Latest Funding Round$15.4M (USD), Series C
Jul 2013
- InvestorsLabCorp
& 6 more
Products & Services of SynapDx
SynapDx offers a comprehensive portfolio of products and services, including Spectros 280 IU, Genotropin 36 IU, Semaglutide 5 mg, and Zptropin 160 IU.
Provides growth hormone for energy and muscle enhancement.
Supports hormone therapy for recovery and performance.
Assists in fat reduction and metabolic health improvement.
Offers hormone for anti-aging and vitality benefits.
Funding Insights of SynapDx
SynapDx has successfully raised a total of $32.75M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $15.4 million completed in July 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $32.75M
- Total Rounds 5
- Last Round Series C — $15.4M
- First Round $9.35M
(Jun 2010)
- Investors Count 7
All 5 funding rounds of SynapDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2013 | $15.4M | Series C | – | Google Ventures | |
| Mar 2013 | – | Series C | – | – | |
| Feb 2013 | $2M | Series C | – | – | |
| Dec 2012 | $6M | Series B | – | – | |
| Jun 2010 | $9.35M | Series A | – | Bain Capital Ventures, General Catalyst | – |
7 investors in total: 7 institutional.
Investors in SynapDx
SynapDx has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include LabCorp, Flare Capital Partners and North Bridge Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage tech startups are funded by this venture capital firm. | – | flarecapital.com | Boston, United States | |
US focused seed to growth stage VC firm | – | northbridge.com | Needham, United States | |
Investment and transformation services for entrepreneurs in technology and finance sectors. | – | generalcatalyst.com | - | |
Corporate backed venture capital fund investing in multiple sectors | – | gv.com | Mountain View, United States | |
Investments and family assets are managed by The Kraft Group. | – | thekraftgroup.com | Foxborough, United States | |
Venture capital fund focused on investing in multiple sectors | – | baincapitalventures.com | Boston, United States | |
Provider of laboratory tests for physicians | 1969 | labcorp.com | Burlington, United States |
Investor details for SynapDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SynapDx
1 people are tracked at SynapDx (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jeffery Luber | Co-founder, Vice President Corporate Development | Leadership |
Complete people profiles for SynapDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SynapDx
3 dated milestones of SynapDx across 3 years, from founding to its latest funding, stage changes and deals.
- Founded SynapDx is founded.
- Funding First funding round of $9.3M.
- Funding Latest funding round, Series C, of $15.4M.
Competitors of SynapDx
SynapDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Linus Biotechnology, Lineagen, MARAbio, SensOmics and Pediatric Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| linusbio.com | 2020 | New York, United States | $47.65M | – | Developer of diagnostic tests for central nervous system and gastrointestinal disorders | |
| lineagen.com | 2002 | Salt Lake, United States | $66.93M | 40 | Sequencing-based diagnostic tests and services for autism are provided. | |
| marabio.com | 2016 | Salt Lake, United States | $19.06M | – | A blood test for maternal autoantibody-related autism is developed. | |
| sensomics.com | 2007 | Toronto, Canada | – | – | Precision medicine for children's health is provided through genomic integration. | |
| pediatricbioscience.com | 2006 | Sacramento, United States | $2.44M | – | Provides blood biomarker-based diagnostics for autism spectrum disorders. | |
| autism-biotech.com | 2011 | Belfast, United Kingdom | $51,300 | – | Develops biochemical tests for early autism diagnosis. | |
| neuropointdx.com | 2006 | Madison, United States | – | – | Metabolomics for neuro-developmental disorders | |
| fbbbio.com | 2020 | Coralville, United States | $401,000 | – | In-vitro diagnostic tests for COVID-19 and neurological diseases are developed. | |
| neuraclegen.com | 2018 | Seoul, South Korea | – | – | Develops gene therapies using adeno-associated virus technology to treat various diseases. |
Detailed competitors of SynapDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synapdx
Complete news archive for SynapDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SynapDx
10 companies that operate in the same segment as SynapDx (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SynapDx
SynapDx was founded in 2010.
SynapDx is headquartered in Southborough, United States. It is registered at Southborough, Massachusetts, United States.
SynapDx is a funded company, having raised a total of $32.75M across 5 funding rounds to date. The company's 1st funding round was a Series A of $9.35M, raised on Jun 2010.
SynapDX operates as an online retailer specializing in human growth hormone (HGH) products, including injections and pens, to enhance energy, muscle growth, and recovery. It provides lab-tested items with fast delivery options, targeting adults focused on fitness and anti-aging. The platform emphasizes safe purchasing, verified brands, and customer support, while advising medical consultation for use.
SynapDx's top competitors include Linus Biotechnology, MARAbio and Lineagen.
SynapDx offers Spectros 280 IU, Genotropin 36 IU, Semaglutide 5 mg, and Zptropin 160 IU.
SynapDx has 7 investors. Key investors include LabCorp, Flare Capital Partners, North Bridge Venture Partners, General Catalyst, and Google Ventures.
SynapDx operates through Thesah.